Please ensure Javascript is enabled for purposes of website accessibility

Why Pfizer Popped This Morning

By Brian D. Pacampara, CFA – Feb 4, 2014 at 10:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Does this analyst make a good case? Or is it just more noise from Wall Street?

While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense.

What: Shares of Pfizer (PFE -0.12%) gained over 2% this morning after Jefferies upgraded the pharmaceutical giant from hold to buy.

So what: Along with the upgrade, analyst Jeffrey Holford boosted his price target to $38 (from $33), representing about 24% worth of upside to yesterday's close. While momentum traders might be turned off by the stock's sluggish action in recent months, Holford thinks Pfizer is too juicy to pass up given its growth and margin enhancement opportunities.

Now what: Jefferies raised its 2014 earnings-per-share outlook for Pfizer from $2.24 to $2.27 and its 2015 view from $2.33 to $2.37. "Oncology and restructuring are key themes for the Pharma sector," noted Holford. "Pfizer has both with [breast cancer drug] palbociclib looking like it could launch before year end, while management look to give increased visibility on a new organizational structure from Q1'14." When you couple those solid prospects with Pfizer's peer-lagging forward P/E of 13, it's tough to disagree with Jefferies' bullish stance. 

Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$51.72 (-0.12%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.